OP Ohr Pharmaceutical Inc Stock: price and management transactions · United States · SEC (Form 4)Follow the Ohr Pharmaceutical Inc share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). The latest transaction was reported on 20 January 2016 (Acquisition). Among the most active insiders: Slakter Jason Scott. All data is openly available.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 20 January 2016
All Executives20 Thresholds0 Prospectus0 Other0
Declarations 20 total
▲ Chief Executive Officer · Executives · 19 Jan 2016
100 shares Common Stock, par value $0.0001 per share SEC:0001387131-16-003930:0
Canonical exit: 18 Apr 2016 (T+90) ▲ Chief Executive Officer · Executives · 19 Jan 2016
200 shares Common Stock, par value $0.0001 per share SEC:0001387131-16-003930:1
Canonical exit: 18 Apr 2016 (T+90) ▲ Chief Executive Officer · Executives · 19 Jan 2016
500 shares Common Stock, par value $0.0001 per share SEC:0001387131-16-003930:2
Canonical exit: 18 Apr 2016 (T+90) ▲ Chief Executive Officer · Executives · 19 Jan 2016
400 shares Common Stock, par value $0.0001 per share SEC:0001387131-16-003930:3
Canonical exit: 18 Apr 2016 (T+90) ▲ Chief Executive Officer · Executives · 19 Jan 2016
200 shares Common Stock, par value $0.0001 per share SEC:0001387131-16-003930:4
Canonical exit: 18 Apr 2016 (T+90) ▲ Chief Executive Officer · Executives · 19 Jan 2016
100 shares Common Stock, par value $0.0001 per share SEC:0001387131-16-003930:5
Canonical exit: 18 Apr 2016 (T+90) ▲ Chief Executive Officer · Executives · 19 Jan 2016
200 shares Common Stock, par value $0.0001 per share SEC:0001387131-16-003930:6
Canonical exit: 18 Apr 2016 (T+90) ▲ Chief Executive Officer · Executives · 19 Jan 2016
200 shares Common Stock, par value $0.0001 per share SEC:0001387131-16-003930:7
Canonical exit: 18 Apr 2016 (T+90) ▲ Chief Executive Officer · Executives · 19 Jan 2016
200 shares Common Stock, par value $0.0001 per share SEC:0001387131-16-003930:8
Canonical exit: 18 Apr 2016 (T+90) ▲ Chief Executive Officer · Executives · 19 Jan 2016
200 shares Common Stock, par value $0.0001 per share SEC:0001387131-16-003930:9
Canonical exit: 18 Apr 2016 (T+90) ▲ Chief Executive Officer · Executives · 19 Jan 2016
400 shares Common Stock, par value $0.0001 per share SEC:0001387131-16-003930:10
Canonical exit: 18 Apr 2016 (T+90) ▲ Chief Executive Officer · Executives · 19 Jan 2016
100 shares Common Stock, par value $0.0001 per share SEC:0001387131-16-003930:11
Canonical exit: 18 Apr 2016 (T+90) ▲ Chief Executive Officer · Executives · 19 Jan 2016
100 shares Common Stock, par value $0.0001 per share SEC:0001387131-16-003930:12
Canonical exit: 18 Apr 2016 (T+90) ▲ Chief Executive Officer · Executives · 19 Jan 2016
850 shares Common Stock, par value $0.0001 per share SEC:0001387131-16-003930:13
Canonical exit: 18 Apr 2016 (T+90) ▲ Chief Executive Officer · Executives · 19 Jan 2016
1,200 shares Common Stock, par value $0.0001 per share SEC:0001387131-16-003930:14
Canonical exit: 18 Apr 2016 (T+90) ▲ Chief Executive Officer · Executives · 19 Jan 2016
1,000 shares Common Stock, par value $0.0001 per share SEC:0001387131-16-003930:15
Canonical exit: 18 Apr 2016 (T+90) ▲ Chief Executive Officer · Executives · 19 Jan 2016
100 shares Common Stock, par value $0.0001 per share SEC:0001387131-16-003930:16
Canonical exit: 18 Apr 2016 (T+90) ▲ Chief Executive Officer · Executives · 19 Jan 2016
200 shares Common Stock, par value $0.0001 per share SEC:0001387131-16-003930:17
Canonical exit: 18 Apr 2016 (T+90) ◆ Chief Financial Officer · Executives · 7 Jan 2016
130,000 shares Common Stock, par value $0.0001 per share SEC:0001387131-16-003869:0
◆ Chief Executive Officer · Executives · 7 Jan 2016
350,358 shares Common Stock, par value $0.0001 per share SEC:0001387131-16-003867:0
About Ohr Pharmaceutical Inc Ohr Pharmaceutical Inc is a biopharmaceutical company focused on developing treatments for eye diseases. The company is listed on NASDAQ under the ticker OHRP.